Literature DB >> 1727896

Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.

K Oishi1, N L Koles, G Guelde, M Pollack.   

Abstract

In vitro and in vivo antibacterial and protective properties of murine monoclonal antibodies (MAbs) to Escherichia coli O111:B4 lipopolysaccharide (LPS) were evaluated in relation to antibody isotype and complement-fixing activity. Six O side chain-specific MAbs, including two IgMs and one of each IgG subclass, were analyzed for quantitative binding and C3 deposition on intact bacteria, complement-mediated bactericidal and opsonophagocytic activity, and protection against intraperitoneal infections in mice. Although C3 was deposited on bacteria in the presence of normal human serum (NHS) alone, LPS-specific MAbs increased C3 attachment in a dose-dependent manner. Bacterial killing occurred only in the presence of both antibody and complement NHS and required an intact alternative pathway. The efficiency of bacterial killing varied by antibody isotype (IgM greater than IgG2a greater than other IgG subclasses) and correlated with C3-fixing capacity. Opsonophagocytic activity of MAbs exhibited a similar isotype-related rank order. Likewise, IgM was more active than IgG, and IgG2a was superior to other IgG subclasses, in MAb-mediated protection against intraperitoneal infection. These data document the interdependent antibacterial and complement-fixing properties of LPS-reactive MAbs and the degree to which both activities are determined by antibody class and isotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727896     DOI: 10.1093/infdis/165.1.34

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

1.  CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.

Authors:  Hang Xie; Ihsan Gursel; Bruce E Ivins; Manmohan Singh; Derek T O'Hagan; Jeffrey B Ulmer; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Antibody response specific to the capsular polysaccharide is impaired in Streptococcus suis serotype 2-infected animals.

Authors:  Cynthia Calzas; Paul Lemire; Gael Auray; Volker Gerdts; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

3.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

4.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

5.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.

Authors:  K Oishi; F Sonoda; A Iwagaki; S Kobayashi; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Protective murine monoclonal antibodies to Cryptococcus neoformans.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.

Authors:  K Oishi; F Sonoda; A Iwagaki; P Ponglertnapagorn; K Watanabe; T Nagatake; A Siadak; M Pollack; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Acute lung injury induced by lipopolysaccharide is independent of complement activation.

Authors:  Daniel Rittirsch; Michael A Flierl; Danielle E Day; Brian A Nadeau; Stephanie R McGuire; Laszlo M Hoesel; Kyros Ipaktchi; Firas S Zetoune; J Vidya Sarma; Lin Leng; Markus S Huber-Lang; Thomas A Neff; Richard Bucala; Peter A Ward
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.